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Inhibition of mitogenesis and c-fos induction in mesangial cells by
heparin and heparan sulfates
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Inhibition of mitogenesis and c-los induction in mesangial cells by
heparin and heparan sulfates. When rat renal mesangial cells (RMC) or
vascular smooth muscle cells are released from quiescence by serum
stimulation they express c-fos mRNA transiently at 30 to 60 minutes and
progress in synchrony to S phase. Heparin causes significant suppression
of [3H]-thymidine incorporation into DNA in S phase and a decrease and
delay of entry of cells into S/G2. Added at the time of serum stimulation,
heparin (1 j.g/ml or less) causes a decrease in the subsequent expression
of c-fos mRNA in RMC, and a similar effect is observed with heparan
sulfate chains isolated from RMC-cultures themselves. Although these
cells internalize and degrade heparin, the timing of the maximal effect
indicates an extracellular action of heparin. In keeping with this idea,
'251-heparin binds specifically to a single class of high affinity sites on the
cell surface. The effect of heparin on c-fos induction may be independent
of interaction with cytokines or cytokine receptors; its magnitude is not
diminished when heparin-binding substances are removed from serum by
heparin-Sepharose. Furthermore, direct activation of protein kinase C
(PKC) with a phorbol ester in the absence of serum likewise induces c-fos
and 1 xg/ml heparin inhibits this response by 65%. Phorbol ester caused
an increase in the proportion of histone Hi-active PKC associated with
the cell membrane fraction, from approximately 25% to 70% of total
activity. Heparin affected neither the total activity of the kinase nor the
proportion associated with the membrane. When PKC was inhibited with
staurosporine, only very low levels of c-fos were induced by serum. We
conclude that low concentrations of heparin and heparan sulfate suppress
the mitogenic response of mesangial cells to serum and inhibt c-fos mRNA
induction through an effect of cell surface-bound glycosaminoglycan on a
signalling pathway downstream of PKC.
Heparin is an anionic glycosaminoglycan possessing a charac-
teristic disaccharide repeat sequence of alternating glucosamine
and uronic acid sugars. Following the discovery that heparin
inhibits smooth muscle cell (SMC) proliferation in vivo [1],
heparin and other glycosaminoglycans were shown similarily to
inhibit SMC proliferation in culture [2, 3], affect cell cycle kinetics
[4], alter protein synthesis and secretion [5—7], and decrease
motility [8]. Heparin also modulates proliferation in the context of
extracellular matrix [9]. Suggestive of a common mechanism for
these activities, heparin has been shown to inhibit selectively the
protein kinase C (PKC) -dependent pathway of signal transduction
[10, 11] and prevent activation of mitogen-activated protein
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kinase (MAPK) [12] at concentrations of 100 to 200 tg/ml. It will
also down-regulate the number of EGF receptors on the cell
surface [13], and suppress binding and mitogenesis of bFGF and
other protein factors in some cells [14—16]. However, which of
these effects is necessary for growth inhibition is unknown, and
the relevance of these high concentrations remains unclear.
Although the mechanism(s) of heparin's antiproliferative ac-
tion remains largely unknown, it is established that it binds to the
SMC surface and is subsequently internalized [17]. It has been
demonstrated that heparin's anticoagulant properties are not
necessary for its antiproliferative effect [18] and that other
glycosaminoglycans, pentosan polysulfate, and other polyanionic
compounds affect the rate of proliferation of a number of different
cell types [19—22]. However, these presumably electrostatic mim-
ics of heparin do not display its full range or potency of effects.
Furthermore, heparin-like species isolated from SMC, endothe-
hal, epithelial and rat mesangial cell (RMC) cultures are potent
inhibitors of SMC or RMC cell growth [2, 23—25], suggesting that
heparan sulfates may play an important physiological role by
acting in paracrine or autocrine roles to regulate cell growth.
The mesangial cell is a reasonable model in which to explore
the physiological relevance of the antiproliferative activity of
heparin-like molecules. In healthy adult kidney, mesangial cells
have very low rates of growth and turnover [26]. The proliferation
of glomerular mesangial cells is a prominent early histological
feature of many glomerular diseases in humans and experimental
animals [27, 28]. Heparin treatment was able to suppress the
formation of hypercellular mesangial nodules in the focal mesan-
gioproliferative disease induced by injecting Habu snake venom
into rats [29]. Recently, heparin has been shown to prevent
albuminuria and to reverse the mesangial expansion occurring in
diabetic rats [30, 31], and to suppress mesangial cell proliferation
and matrix expansion in experimental mesangioproliferative gb-
merubonephritis [321. It also reduces the mesangial hypercellular-
ity that develops in chronic aminonucleoside nephrosis [33], but
does not affect endocapillary proliferation in the progressive
Masugi nephritis model [34]. These observations suggest that
under some circumstances heparin may suppress mesangial cell
proliferation and matrix secretion in vivo, perhaps by augmenting
the actions of endogenous heparan sulfates.
We have previously shown that heparin, as well as endogenous
heparan sulfates produced by cultured RMC, are potent negative
regulators of RMC growth in vitro [25]. The present study was
undertaken to investigate the points of this action of heparin and
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heparan sulfates during the cell cycle, and to examine the mecha-
nisms by which low concentrations of heparin may exert an antipro-
liferative effect on these cells.
Methods
Materials
NuSerum was a product of Collaborative Biomedical Products
(Bedford, MA, USA). Other culture media and fetal bovine se-
rum (FBS) were obtained from Gibco/BRL (Burlington, Ontario,
Canada). [3H]thymidine (6.7 Ci/mmol) and sodium [1251]iodide
(carrier free) were from ICN (Mississauga, Ontario, Canada),
and [a-32P]dCTP (3000 Ci/mmol) and [y-32P]ATP (10 to 50
Ci/mmol) were from Du Pont Canada (Mississauga). Heparan
sulfate (bovine kidney), dermatan sulfate (porcine skin), chon-
droitin sulfate type C (shark cartilage), hyaluronic acid (bovine
trachea), dextran sulfate (average Mr 500 kD), trypsin (bovine
pancreas), chondroitinase ABC, and 1,2-diolein were from Sigma
(St. Louis, MO, USA). Because commercial heparin preparations
show batch-to-batch variation in their antiproliferative effects
[35], a single lot (no. 50H0010) of Sigma bovine lung heparin
(average M 15 kD as reported by the manufacturer and con-
firmed by Sepharose 6B chromatography with the calibration data
of Wasteson [36]) was used for all the experiments reported here.
Anhydrous hydrazine, SHPP-sulfate, and IodoBeadsTM were
from Pierce (Rockford, IL, USA). Hydrazine sulphate was from
BDH (Toronto, Ontario, Canada) and iodic acid was from Fisher
Scientific (Fair Lawn, NJ, USA). Propidium iodide and 12-0-
tetradecanoyl phorbol-13-acetate (TPA) were from Calbiochem-
Novabiochem (La Jolla, CA, USA). RNase, leupeptin, and his-
tone Hi were from Boehringer Mannheim Canada (Laval,
Quebec, Canada). Phosphatidylserine was a product of Supelco
(Oakville, Ontario, Canada). A rat c-fos cDNA was cloned by
Curran et al [37] and obtained from T. Cruz (University of
Toronto). Rat glyceradehyde-3-phosphate dehydrogenase cDNA
[38] was provided by W.A. Border (University of Utah). Sephadex
G-50, DEAE-Sephacel, pre-packed PD-b columns, pre-packed
NICK Spin columns, and Sephacryl S-300 HR were from Phar-
macia (Montreal, Quebec, Canada). Pre-packed C18 SEP columns
were from Chromatographic Specialties (Brockville, Ontario,
Canada). Affi-Gel Heparin was from BioRad (Richmond, CA,
USA).
Preparation of HSJ and HS2
Preparative scale isolation of RMC cell layer and conditioned
medium heparan sulfates (HS1 and HS2, respectively) was as
described previously [25]. Briefly, medium and cell layer extracts
were subjected to sequential chromatography on Sephadex G-50,
DEAE-Sephacel, C18-Sepharose, and Sephacryl S-300. Pooled
fractions from Sephacryl of both cell layer and medium were
desalted and concentrated by ultrafiltration against YM1O mem-
branes (10 kD cut-off; Amicon, Beverly, MA, USA). HS1 and HS2
were isolated by DEAE-Sephacel chromatography after chon-
droitinase ABC digestion and then desalted. For quantitation of
glycosaminoglycan, desalted fractions were analyzed by the dim-
ethylmethylene blue colorimetric assay [39] against a standard
curve prepared from heparin.
Cell culture and characterization
Rat mesangial cells (RMC) were prepared from glomeruli of
100 g male Wistar rats following the procedure of Simonson and
Dunn [40] and characterized by their morphology and positive
staining for desmin and smooth muscle actin [41] as described
previously [25]. They were used between passages 5 and 15 when
they contracted in response to angiotensin II and endothelin and
exhibited growth suppression in the presence of heparin (1
g/ml). The AlO smooth muscle cell line originating from embry-
onic rat aorta [421 was obtained from the American Type Culture
Collection (ATCC # CRL 1476). Both cell types were cultured in
RPMI 1640 containing 10% FBS. Cell viability was greater than
95% during the experiments reported here, as determined by
Trypan blue exclusion.
Mitogenic assay
Cells were growth-arrested in 0.4% FBS for 48 hours and then
stimulated with 5% NuSerum in RPMI 1640 at time zero, with or
without heparin, HS1, or HS2 at concentrations reported in
individual experiments. An initial plating density was chosen that
produced cultures at approximately 90% confluence (6 X io
cells/cm2) at time zero. At 16 hours, thymidine incorporation was
measured by pulse-labeling cells in 12 well culture plates with 2
Ci of [3HJ-thymidine in 1 ml of serum-free medium for 30
minutes. At the end of that time, acid-precipitable label was fixed
to the plastic surface with ice-cold 5% trichloroacetic acid (TCA)
[43] and solublized with 0.2 N NaOH/1% SDS for liquid scintilla-
tion counting. To investigate heparin-sensitive time points in the
cell cycle, heparin was added to cultures at 0, 0.25, 0.5, 1, 2, 4 and
8 hours after stimulation with NuSerum. In some experiments,
growth-arrested RMC were stimulated with 5% NuSerum that
had been passed through an Affi-Gel Heparin (heparin-Sepha-
rose) affinity column to remove heparin-binding factors [44].
NuSerum (2 ml) was chromatographed on 2 ml of heparin-
Sepharose pre-equilibrated with PBS. After loading, the column
was washed with PBS until the A280 was < 0.1. The total eluate
(14 ml) was concentrated to 2 ml in a Centricon-10 tube (Amicon)
and then filter-sterilized.
Cell cycle analysis
Growth-arrested RMC were released from G0 with 5%
NuSerum with or without heparin (1 j.g/ml). At 0, 8, 16, 18 and 24
hours after stimulation RMC were removed from the culture dish
by trypsinization and collected by centrifugation at 300 >< g for five
minutes. Nuclei were prepared for flow cytometry by methanol
fixation and propidium iodide staining. Briefly, cells were sus-
pended in ice cold PBS to (ito 2) X 106 cells/ml. Methanol (2 ml)
was added drop-wise into 1 ml of cell suspension from a Pasteur
pipette while mixing the cells on a vortex mixer. After incubating
for 30 minutes on ice, cells were collected by centrifugation at 300
X g for five minutes and resuspended in 500 jil of staining solution
(10 mg propidium iodide, 0.1 ml Triton X-100, 3.7 mg EDTA in
100 ml PBS) by mixing gently on a vortex mixer. The samples were
mixed with RNAse solution (200 units RNase/ml in PBS) and
incubated in the dark at room temperature for 30 minutes. DNA
histograms were obtained on a Epics Elite flow cytometer
(Coulter Electronics, Hialeah, FL, USA) within one hour and
analyzed using Multicycle software from Phoenix Flow Systems
(San Diego, CA, USA).
Northern hybridization analysis
Total RNA was isolated from synchronized cells in 75 cm2
culture plates by lysis in guanidine isothiocyanate and extraction
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with phenol/chloroform using a Promega RNAgentsTM total
RNA isolation kit (Fisher Scientific, Fairlawn, NJ, USA). Equal
amounts of RNA (ca. 10 tg) were denatured by the method of
Gong [45], separated by electrophoresis on agarose-formaldehyde
gels (1.2% agarose, 2.2 M formaldehyde, 1 mM EDTA, 5 mM
NaOAc and 20 mi MOPS, pH 7.0), and transferred by overnight
capillary blotting to Hybond-N nylon membranes (Amersham
Canada, Oakville, Ontario, Canada). Membranes were pre-hy-
bridized for 15 minutes at 65°C in Quik Hyb hybridization
solution (Stratagene, La Jolla, CA, USA). Hybridization was
carried out at 65°C for one hour in Quik Hyb solution containing
500 tg/ml heat-denatured salmon sperm DNA and cDNA probes
labeled with [a-32P]dCTP by the random primer method using a
kit from Gibco/BRL. After hybridization, blots were washed twice
for 15 minutes at 42°C in 2 >< standard saline citrate (SSC)/0.1%
SDS, once for 30 minutes in 1 >< SSC/0.1% SDS and an additional
30 minutes in 0.1 x SSC/0.1% SDS. Where indicated, mRNA
levels were quantitated by densitometry of Northern blot signals
and normalized to 28S rRNA visualized on the ethidium bromide-
stained agarose gel.
lodination of heparin
Heparin (150 mg) was N-deacetylated by dissolving in 3 ml of
anhydrous hydrazine containing 1% hydrazine sulphate and heat-
ing at 100°C for six hours [46]. The reaction mixture was freeze-
dried and the residue was dissolved in 7.5 ml of 0.25 M H103 on
ice. The small amount of 12 that formed was extracted with 10 ml
of ether three times and the sample was desalted on a pre-packed
PD-b column. Approximately 10 ml of desalted sample was
loaded on a 5 ml DEAE-Sephacel column pre-equilibrated with
DEAE-buffer (0.2 M NaC1/50 m sodium acetate, pH 5.9). After
washing with 30 ml of DEAE buffer, the sample was eluted with
15 ml of 3 M NaCI/50 m sodium acetate, pH 5.9, and desalted on
a PD-b column. Heparin-SHPP was prepared by mixing 500 sl
(3.1 mg) of desalted sample with 500 jl of 0.2 M borate buffer, pH
8.5, and adding 0.2 ml of DMSO containing 0.24 mg SHPP-sulfate
[47]. The reaction mixture was agitated for 30 minutes at 0°C. One
ml of 0.2 M glycine in 0.1 M borate buffer, pH 8.5, was added to
react with unmodified ester for 10 minutes on ice [48]. The
mixture was applied to 0.5 ml DEAE-Sephacel pre-equilibrated
with DEAE buffer and washed with 3 ml of DEAE buffer. The
sample was eluted with 2.5 ml of elution buffer and desalted on a
PD-b column. Ten microliters of Na25I (0.15 mCi) was dissolved
in 250 d of 0.1 M Tris-HCI, pH 8.8, incubated with an Jodo-
BeadTM at room temperature for five minutes, and mixed with 16
g of desalted heparin-SHPP in 40 l of water. After 15 minutes
at room temperature unincorporated Na1251 was removed on a
NICK Spin column. The specific activity of heparin prepared in
this manner was Ca. 2.0 mCi/mg. Heparin concentrations were
monitored by the dimethylmethylene blue assay.
Binding and uptake studies
Cells grown in 12-well plates were washed three times with
ice-cold PBS and cooled to 4°C for 30 minutes in PBS. Pre-cooled
1251-heparin in PBS containing 0.1% bovine serum albumin and 5
mM MgCI2 [49] was added to triplicate wells. After incubation on
ice, medium was collected and cells were washed five times with
PBS and solublized in 0.2 M NaOH/1% SDS for liquid scintillation
counting. Nonspecific binding was determined with a 100-fold
excess of unlabeled heparin and was approximately 5% of the
total cpm bound. Internalization of 1251-heparin was observed in
the presence of 5% NuSerum. Growth-arrested cells were washed
three times with ice-cold PBS and cooled to 4°C for 30 minutes in
PBS. Pre-cooled RPMI 1640 containing 5% NuSerum and 125I
heparin (0.5 ig/ml) was added to the cells and held at 4°C for 60
minutes. Cells were then washed five times with cold PBS and
incubated in medium pre-warmed to 37°C containing 5%
NuSerum. At intervals the supernatants of triplicate cultures were
processed for scintillation counting. The cell layers were incu-
bated in a 100-fold excess of unlabeled heparin for 15 minutes,
treated with trypsin (50 jig/mI) for 15 minutes, and solublized in
0.2 M NaOH/1% SDS for scintillation counting. Cell numbers
were measured in triplicate using a Coulter particle counter.
To observe degradation of internalized heparin, growth-ar-
rested RMC were incubated in medium containing 5% NuSerum
and 1251-heparin (0.5 jig/mi) at 37°C. Heparin bound to the cell
surface was removed by incubating with a 100-fold excess of
unlabeled heparin and treatment with trypsin (0.05% trypsin, 0.53
mM EDTA in PBS) for 15 minutes. The cells were dissolved in
Laemmli SDS-sample buffer [50] for electrophoresis under dena-
turing conditions on precast polyacrylamide 4 to 20% gradient
gels (Novex, San Diego, CA, USA) according to the method of
Laemmli. Fluorography was performed after treating the gels with
EnlightningTM autoradiographic enhancer (New England Nu-
clear, Boston, MA, USA).
Protein kinase C assay
Quiescent RMC were stimulated with 50 ng/ml TPA in the
presence or absence of 1 jig/mi heparin. After 15 minutes of
stimulation, cells were suspended in 3 ml of 2 mrvi EDTA
containing 0.5 m ethylene glycol-bis-(J3-aminoethyl ether)
N,N,N',N'-tetraacetic acid (EGTA), 2 msi phenylmethylsulfonyl
fluoride (PMSF), 25 jig/mi leupeptin, 0.33 M sucrose and 20 mr't
Tris HCI, pH 7.5, and centrifuged at 15,000 X g for 15 minutes as
described by Thomas, Golpalakrishna and Anderson [51]. The
pellets were homogenized with a Dounce homogenizer in 4 ml of
2 mrvi EDTA, 0.5 mM EGTA, 2 mrvi PMSF and 20 mivi Tris HC1,
pH 7.5 (buffer A). The supernatant contains cytosolic PKC. To
solubilize PKC activity associated with the membrane fraction,
Nonidet P-40 was added to the pellet to a final concentration of
1%. The suspension was rotated slowly at 4°C for 30 minutes and
centrifuged to obtain detergent-solubilized PKC from the mem-
brane fraction. To remove endogenous PKC inhibitors and deter-
gent, cytosolic and detergent-solubilized samples were fraction-
ated on 0.5 ml DEAE-Sephacel columns pre-equilibrated with 10
ml of buffer A at 4°C. Columns were washed with two 1.5-mi
aliquots of buffer A prior to elution of PKC with 1 ml of buffer A
containing 100 ifiM NaCi. Leupeptin (25 jig/mI) was added
immediately to eluted fractions. Reaction mixtures for the deter-
mination of PKC activity contained 20 mvi Tris HC1, pH 7.5, 0.75
mM CaC12, 10 mivi Mg(CH3COO)2, 100 jiM [-y-32P]ATP, 25 jig
histone Hi, and 50 jig/mi leupeptin with or without 24 jig of
phosphatidylserine and 1.6 jig 1,2-dioiein in a final volume of 250
jiL. Reaction was initiated by addition of 50 jil of sample
containing PKC. After incubation at 30°C for three minutes the
reaction was terminated by the addition of 1 ml of ice-cold 25%
(wt/vol) TCA and the precipitate was collected by filtration over a
Glass Microfibre filter GF/F (Whatman, Maidstone, UK). The
reaction tubes were washed twice with 2 ml of cold 5% (wt/vol)
TCA and the washings were added to the filters which were then
Co
nt
ro
l 
Se
ru
m
 
H
ep
ar
in
 
C)
 
c-
fo
sm
RN
A l
ev
el
 
a
 
0 
z 
0 
tO
 
C.
) 
I 
w
 
Co
nt
ro
l 
Se
ru
m
 
0 
H
ep
ar
in
 
440 Wang and Templeton: Heparin and mesangial cell proliferation
washed five times (2 mI/wash) with cold 5% TCA and counted by
liquid scintillation. Counts of 32P obtained in the absence of
phophatidylserine and 1,2-diolein were subtracted from those
obtained when the lipids were added just prior to initiating the
reaction.
Results
Effects of heparin and HS on early-response gene expression
Because we previously found that endogenous HS chains can
markedly suppress RMC proliferation at a concentration of I
jig/mi [25] we wondered if this low concentration could regulate
early-response gene expression. RMC released from quiescence
by serum stimulation expressed a mRNA of 2.1 kb that hybridized
to a c-fos cDNA. Expression of this message was apparent at 30
minutes; it was decreased by 72 9% (mean SE from three
independent experiments) by heparin, and to a similar extent by
HS1 and HS2, all at 1 jig/mI (Fig. 1). HS1 and HS2 are heparan
sulfate chains that lack detectable proteoglycan core protein,
isolated from cell layers and conditioned medium, respectively, of
RMC cultures as previously described [251. Because of limited
amounts of material, further studies were carried out with hepa-
nfl.
To determine if the suppression of c-fos expression by low
concentrations of heparin was specific to RMC, AlO cells of
vascular smooth muscle origin were also studied. Under condi-
tions similar to the RMC experiments, heparin caused a decrease
in c-fos mRNA to 56% of control levels (Fig. 1).
Cell cycle analysis
The effect of heparin on the cell cycle distribution of RMC was
studied using flow cytometry. Growth-arrested RMC were stimu-
lated with serum, with or without 1 jig/mi heparin. Based on our
earlier studies of thymidine incorporation in these cells [251 we
anticipated that they would pass through S phase at 16 to 18
hours, and chose bracketing times for analysis. Analysis of the
DNA histograms (Fig. 2) indicates that the cells progress through
the cycle in synchronous fashion. By 18 hours, 72% of the control
cells progressed to S phase, compared to only 46% of the
heparin-treated cells (Table 1). Thirty-two percent of control cells
completed DNA replication at 24 hours, in contrast to only 19%
of the heparin-treated cells.
The expression of c-fos mRNA peaked at about 30 minutes and
the message was undetectable by two hours (Fig. 3). The time
course of induction was the same in control and heparin-treated
cells, demonstrating that the apparent suppression by heparin at
30 minutes was not simply due to a delay in production of c-fos
message. The same Northern blot was probed with a cDNA
encoding GAPDH, as this is a common "housekeeping gene" in
studies of mesangial cells [52, 53]. Serum stimulation caused a
gradual increase through the cell cycle of the characteristic
transcript of GAPDH at 1.3 kb (Fig. 3) and so all signals on the
Northern blots were normalized to the 28S ribosomal RNA
detected by ethidium bromide fluorescence on the original aga-
rose gel. Heparin caused the GAPDH mRNA to remain at basal
levels throughout the cell cycle, suggesting that GAPDH expres-
sion was linked to proliferation in these cells.
Time dependence of heparin 's antimitogenic activity
To determine if the ability of low concentrations of heparin to
decrease the progression of serum-stimulated cells to S phase was
Fig. 1. Regulation of c-fos and GAPDH gene expression by heparin and
heparan sulfates in RMC and vascular SMC. RMC and AlO cells were
rendered quiescent in 0.4% scum for 48 hours (control) and treated with
5% NuSerum for 30 minutes with or without heparin or endogenous
heparan sulfates (HS1 and HS2 as described in the text) at 1 jig/mI. Total
RNA was isolated and analyzed by Northern hybridization at 10 igIlane.
(A) Ethidium bromide-stained gel showing 18S and 28S rRNA and
autoradiograms of the resultant blot following hybridization with eDNA
probes encoding c-fos or GAPDH. (B) Quantitation of hybridization
signals for c-fos normalized to the quantity of 28 S rRNA in the samples
as measured from a negative of the ethidium bromide-stained agarose gel
(not shown).
dependent upon suppression of early c-fos expression, cells were
treated with 0.5 jig heparin/ml at various times after addition of
5% NuSerum to quiescent cultures. When heparin was added at
the same time as serum, incorporation of [3H]-thymidine into
DNA 16 hours later was decreased by about 50% (Table 2). When
Fig. 2. Cell cycle distribution of RMC after
semm stimulation. Quiescent RMC were
stimulated (time zero) with 5% NuSerum with
or without heparin (1 .rglml). At intervals, the
cells were processed for flow cytometry as
described in the Methods section. The fraction
of cells in the G1, S, and G2+M compartments
of the cell cycle was determined using the
Multi-cycle software package (Table 1). DNA
histograms are displayed for certain time points
to demonstrate the relationship between the
different cell cycle compartments and the
antiproliferative effects of heparin.
Table 1. Cell cycle distribution of serum-stimulated RMC
Timea
hr
Heparin
p.g/ml
G0IG1b S G2+M
%
0 — 75.5 24.5 0
8 0
1
70.6
74.0
28.5
26.0
0.9
0
16 0
1
39.9
57.9
60.1
40.7
0
1.5
18 0
1
20.0
53.6
72.0
46.4
0
0
24 0
1
29.0
34.6
39.5
46.5
31.6
18.9
a Quiescent RMC were stimulated (time zero) with 5% NuSerum with
or without heparin (1 gJml). At intervals, the cells were processed for
flow cytometry as described in the Methods section.
bThe fraction of cells in the G01G1, S, and G2IM compartments of the
cell cycle was determined using the Multicycle software package from data
such as those displayed in Fig. 2.
the addition of heparin was delayed for 15 minutes after the
addition of serum [3H]-thymidine incorporation was only de-
creased by about 30%, and this level of suppression remained
when the delay was as long as four hours. This suggests that the
antimitogenic effect of heparin in RMC was partially due to
blockage of a very early event—within the first 15 minutes—after
serum stimulation, and partially due to an additional mecha-
nism(s) operating later during progression through G1.
Binding of heparin to cells
The early action of heparin suggests a mechanism operating at
the cell surface before significant amounts of the glycosaminogly-
can are internalized. Therefore, heparin was radioiodinated to
facilitate studies of the time course of its binding and internaliza-
tion by these cells. lodination did not affect the biological activity
of heparin; the iodinated product showed the same concentration
dependence as the starting material and both caused significant
inhibition of [3HJ-thymidine incorporation in stimulated RMC at
concentrations as low as 100 nglml (Table 3).
Initial binding studies were performed at 4°C to minimize
effects of internalization and isolate the binding event. Under
these circumstances binding was rapid, and saturable by 30 to 60
minutes (Fig. 4a). The increased antimitogenic activity observed
when heparin was added along with serum might be due to differ-
ences in heparin binding to quiescent cells compared to cycling
RMC. Therefore, we compared 1251-heparin binding to quiescent
(serum starved) cultures with binding to sub-confluent cells in the
log phase of growth, and with slowly proliferating confluent
cultures (Fig. 4A). Compared to proliferating cultures, quiescent
cells bound 5- to 10-fold more heparin. Scatchard analysis of these
systems together with quiescent AlO cell cultures indicated a
single major class of binding sites in each (Fig. 4B), and demon-
strated changes in both binding affinity and number of binding
sites with cell type and phase of growth (Table 4). Quiescent RMC
have about 6.6 >< 106 heparin-binding sites per cell with a
dissociation constant of 1.6 x 108 M based on an average
molecular mass of 15 kD. Both the number and affinity of sites
decreased in serum-fed confluent and sub-confluent cultures.
Quiescent AlO cells bound heparin with an affinity comparable to
quiescent RMC (Kd = 1.5 >< 108 M) but had only half the
number of binding sites (Table 4), consistent with the diminished
effect of heparin on c-fos expression in these cells (Fig. 1). This
was also consistent with the observation that higher concentra-
tions of heparin were necessary to inhibit [3HJ-thymidine incor-
poration in AlO cells to the same extent as in RMC (not shown).
The specificity of heparin binding was assessed by measuring
1251-heparin binding in the presence of a 100-fold excess (on a
I I
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442 Wang and Templeton: Heparin and mesangial cell proliferation
3
B
3
a)
z
El
0
D
0 0.5 1 2 4 8 16 24 36
Time, hours
00.51 2 4 8162436
Time, hours
Fig. 3. Regulations of c-fos and GAPDH gene expressions during RMC cell cycle by heparin. RMCs were growth arrested in 0.4% FBS for 48 hours. The
quiescent cells were then treated with 5% NuSerum for 30 minutes with or without heparin (1 jtg/ml). At the times indicated, total RNA was isolated
and analyzed by Northern hybridization at 10 jLg/lane. Hybridization signals for GAPDH (B) and c-fos (D) were quantitated from the autoradiograms
following hybridization with GAPDH (A) and c-fos (C) cDNAs and normalized to the quantity of 28 S rRNA in the samples.
Table 2. Timing of the antimitogenic effect of heparin
Time hr [3H1-thymidine incorporation
Control 100 2
0 50.1 3.0
0.25 70.3 3.0
0.50 71.9 3.3
1.0 77.6 0.4
2 70.5 1.2
4 72.2 1.5
8 87.3 0.5
Growth arrested RMC were stimulated with 5% NuSerum at time zero.
At the times indicated heparin (0.5 /LgIml) was added to the cultures.
After 16 hr, cells were labeled for 30 mm with °Hj-thymidine (2 sCi/ml),
and the incorporation of radioactivity into DNA at that time is expressed
as a percentage of the counts incorporated by control cells stimulated in
the absence of added heparin. Values are mean SE from triplicate wells
of a single experiment and are typical of results obtained in two separate
experiments.
mass basis) of unlabeled heparin, chondroitin and dermatan
sulfates, hyaluronic acid, heparan sulfate, or high molecular mass
dextran sulfate. Among the glycosaminoglycans only heparin itself
blocked binding, indicating specificity of the sites for heparin
Table 3. Antimitogenic effects of heparin and iodinated heparin
on RMC
[Heparini
jxg/ml
% Inhibition
(heparin)
% Inhibition
(iodinated heparin)
0.01 —7±4 —8±17
0.03 6±5 3±18
0.05 3±1 —8±7
0.10 19±6 26±16
0.50 36±7 55±12
1.00 39±7 42±2
Quiescent RMC were stimulated with 5% NuSerum with or without
heparin or iodinated heparin at the concentrations indicated. After 16 hr
they were labeled for 1 hr with [3H-thymidine (2 jsCi/ml). Results are
expressed as the percent inhibition of incorporation of label into DNA and
are the means SE of triplicate determinations.
(Table 5). High molecular mass dextran sulfate (500 kD) was as
effective as heparin itself in blocking binding of '251-heparin,
indicating a charge-dependent component to the binding event.
However, dextran sulfate itself had weak and variable effects on
[3H]-thymidine incorporation (not shown), precluding its use as
an agent to study the role of heparin binding in antimitogenesis.
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Bound, pmol/106 cells
Fig. 4. Time course and Scatchard analysis of '251-heparin binding. (A)
Growth-arrested (•), confluent (U), and growing cultures (0) of RMC
were incubated with '251-heparin (0.5 g/ml) for the indicated time
periods at 4°C. The cells were then washed five times in ice-cold PBS and
processed for liquid scintillation counting. Background counts obtained
when cultures were exposed to '251-heparin in presence of unlabeled
heparin (100 pg/mI) have been subtracted. Results are expressed as cpm
per i03 cells and are the mean SE of triplicates. (B) Growth-arrested
(•), confluent (•) and growing (LI) RMC and growth arrested AlO cells
(0) were exposed to '251-heparin for 60 minutes at 4°C and the cell layers
and supernatants were analyzed for radioactivity. Background counts were
subtracted from the each time point.
Cell type K.(M)a Binding sites/celi°
Quiescent RMC 1.6 X 10_s 6.6 X 106
Growing RMC
Confluent RMC
7.3 X 10—8
1.8 X iO
3.7 X 106
3.2 x 106
Quiescent AlO cells 1.5 X 10—8 3.6 )< 106
"RMC and AlO cells in the indicated stages of growth were treated with
different concentrations of 1251-heparin for 60 minutes at 4°C and then
radioactivity was counted in the supernatant and cell layer. Dissociation
constants and numbers of binding sites were calculated by Scatchard
analysis.
Competitor cpm bound/I 02 cells°
None 31.0 2.3
Heparin 2.0 0.3
Dextran sulfate 1.6 0.2
Dermatan sulfate 22.0 0.6
Heparan sulfate 25.4 0.9
Chondroitin sulfate 31.5 4.1
Hyaluronic acid 33.0 5.0
° Growth-arrested RMC were incubated in 0.5 jzg/ml 1251-heparin for 60
minutes at 4°C with or without a 100-fold mass excess of the indicated
glycosaminoglycans or dextran sulfate. Results are expressed as cpm
bound per 102 cells and are the means SE of triplicate determinations.
20
Fig. 5. Internalization of '251-heparin bound to the RMC surface. Growth-
arrested RMC were incubated in '251-heparin for 60 minutes at 4°C,
washed five times in ice cold PBS and then warmed to 37°C. At the
indicated times, the supernatant (U) was processed for liquid scintillation
counting. The cells were washed three times and incubated in a 100-fold
excess of unlabeled heparin for 15 minutes followed by exposure to trypsin
(50 pg/mI) for 15 minutes. Heparin-displaceable (0) and trypsin-releas-
able (El) 125J were determined. The residual cell layer was solublized in
sodium hydroxide prior to scintillation counting (S). Results are ex-
pressed as cpm per i03 cells and are the mean SE of triplicates.
A Table 4. Binding of 1251-heparin to RMC and AlO cells
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Internalization of '251-heparin
To determine whether or not heparin was internalized by RMC,
we exposed growth arrested cultures to 1251-heparin at 4°C for one
hour followed by incubation at 37°C. Counts that were not
displaced by excess heparin or removed by trypsinization were
considered to be internalized. Within one hour, 52% of the bound
label was released into the medium. Of the 48% that remained
associated with the cell, approximately half was internalized by
two hours (Fig. 5). To determine if the internalized label was
associated with intact or fragmented heparin during G1, quiescent
RMC were stimulated with 5% NuSerum containing '251-heparin
(5 x iO cpm, total concentration 0.5 .tg/ml). The cells internal-
ized the intact labeled heparin and degraded it to lower Mr species
over several hours (Fig. 6).
Mechanism of inhibition by heparin
Because the timing of its internalization in relation to the
induction of c-fos indicated a role of extracellular heparin, we
D 26.9
1,
18.1i 7.70
40
Fig. 6. Uptake and degradation of '251-heparin by
RMC. Growth-arrested RMCs were incubated in
5% NuSerum containing '251-heparin (0.5 gIml,
5 x iO cpm). At the indicated times, the cells
were washed three times and treated sequentially
with excess heparin and trypsin (0.5 mg/mI in 0.53
mM EDTA) for 15 minutes. The cells were col-
lected by centrifugation, solublized in Laemmli
sample buffer, electrophoresed on 5 to 20%
gradient polyacrylamide gels, and visualized by
autoradiography (A). The lane marked Control
shows the '251-heparin preparation. The position
of molecular mass protein standards is indicated
on the ordinate of panel (A). Heparin- and
trypsin-resistant 125!, considered to be internal-
ized, was counted and normalized to cell number
(B).
examined whether our observations could be a consequence of
interaction of heparin with growth factors or growth factor
receptors. First, NuSerum was passed through a heparin-Sepha-
rose column to deplete it of heparin-binding factors. Compared
with untreated NuSerum, stimulation of quiescent cells with 5%
column-exposed NuSerum resulted in 78 6% (mean SE; N =
6, two separate experiments) of the [3H1-thymidine incorporation
caused by untreated serum at 16 hours. This indicated that part of
the stimulatory activity of NuSerum may be due to heparin-
binding molecules. However, the antimitogenic action of heparin
was not due to interference with these factors; inclusion of
heparin at 1 ig/ml along with column-treated NuSerum decreased
[3H}-thymidine incorporation to 37 4% of control values.
The above experiment does not rule out possible interactions
with heparin binding substances because they may not have been
completely removed by the heparin-Sepharose column. There-
fore, in order to examine further whether the inhibitory effect of
heparin on serum-stimulated cells could be independent of
growth factor/growth factor receptor interactions, quiescent cells
were exposed to a phorbol ester. Because high concentrations of
heparin (100 to 200 g/ml) inhibit protooncogene induction in
TPA-stimulated vascular smooth muscle cells [10, 11], we added
TPA to quiescent cultures of RMC with or without heparin, and
observed the subsequent induction of c-fos. In these circum-
stances, any induction of c-fos was independent of growth factors
or cytokines. In three independent experiments with different
passages of RMC, heparin caused a decrease of 66 12% (mean
SE) in the intensity of the c-fos eDNA-hybridizing band, normal-
ized to 28S RNA. A typical blot is shown in Figure 7. RMC failed
to respond to TPA with c-fos induction following down-regulation
of PKC by a 24 hour exposure to TPA. They also failed to induce
c-fos in response to serum in the presence of the PKC inhibitor
staurosporine (Fig. 7), further supporting the interpretation of
PKC-dependent induction of c-fos in these experiments.
Concluding from the above that extracellular heparin at con-
centrations of 1 j.Lg/ml or less is capable of inhibiting the induction
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Table 6. Effect of heparin on translocation of PKC
TPA24hr —
Fig. 7. Effect of heparin on phorbol ester-stimulated induction of c-fos.Quiescent cultures of RMC were were stimulated with phorbol ester
(TPA, 50 nglml)) with or without heparin (Hep, 1 jrg/ml) and the
experiment was repeated with cells that had been pre-treated with 200
nglml TPA for 24 hours to down-regulate PKC. Control cells were also
stimulated with 5% NuSerum with or without staurosporine (Staur, 50
j.rglml). Total RNA was isolated from quiescent cells at time zero or from
TPA- or serum-stimulated cells at 30 minutes and a Northern blot was
probed with a eDNA encoding c-fos. The relative RNA levels are
corrected for the amount of 28 S RNA in each lane after densitometry.
The effect of heparin on TPA-stimulated cells was confirmed in three
independent experiments (see text); the results of a typical experiment are
shown.
of c-fos mRNA in RMC by serum or phorbol ester, we examined
whether heparin affected the activation/translocation of PKC, or
acted downstream en route to c-fos induction. In two independent
experiments, TPA caused a substantial increase in membrane-
associated PKC activity without influencing total activity. Neither
the total activity nor the TPA-dependent increase in the mem-
brane-associated activity were influenced by heparin (Table 6),
indicating that heparin acts downstream of PKC activation to
inhibit phorbol ester-induced c-fos expression.
Discussion
By examining the antiproliferative effect of heparin on various
cell types, Castellot, Cochran and Karnovsky [4] found that only
smooth muscle cells (SMC) and mesangial cells were significantly
inhibited by heparin at concentrations below 10 tgIml. Other cells
required at least 200 j.tg heparin/ml to show the same effect. The
Cells Total 32P cpm a Membrane 32P % a
Control 24,950 2,770 26 5
TPA 18,890 6,710 65 9
TPA + heparin 20,190 1,040 74 13
a PKC activity was assayed by histone Hi phosphorylation as described
in Methods in RMC rendered quiescent by 48 hours in 0.4% serum
(control) and 15 minutes after stimulation with TPA (50 ng/mI) with or
without heparin (1 pg/mi). The total cpm of 32P incorporated into histone
in response to membrane and supernatant fractions is given as range for
two independent experiments, as is the percentage of cpm in the mem-
brane fraction.
that heparin decreased the serum-induced expression of c-fos and
c-myc. However, Reilly et a! [56] found that in vascular SMC
heparin had no appreciable effect on the induction of either
mRNA by serum. Interestingly, Pukac et al [57] subsequently
showed that very high concentrations of heparin (200 g/ml) can
suppress c-fos and c-myc mRNA in vascular SMC, an effect we
observe on c-fos in RMC and an established vascular SMC line at
only 1 jig/rn!. Since heparin binds to most cells with K. values
between 10—8 M and 10_in M [17, 19, 49, 581, the concentration of
heparin effectively inhibiting c-fos expression should be lower than
10 jig/mi (ca. 7 >< iO M) if cell binding is important in the
mechanism (see below). The discrepant observations both with
respect to heparin's antimitogenic effect at these concentrations
and its ability to suppress c-fos expression in SMC may partially be
explained by the recent finding that under certain conditions
vascular SMC populations can give rise to heparin-resistant cells
[59]. From the present study it appears that heparin is effective at
low concentrations in heparin-sensitive cells that may more closely
resemble RMC and SMC in vivo.
Although heparin did not block PKC translocation/activation
after TPA treatment, and in fact has been shown to enhance
PKC-dependent phosphorylation of histone Hi in vitro [60], it still
suppressed the c-fos induction about threefold. This supports the
view that heparin acts downstream of PKC to block PKC-induced
early-response gene expression. Possible sites of action include
cell surface binding sites and intracellular targets of the glyco-
saminoglycan or its metabolites. Several lines of evidence in the
present study point to an important role for surface binding in
c-fos
2
0
z
E
C
a)0
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present study shows that heparin can exert a significant antimito-
genie effect on RMC at a concentration as low as 0.1 jig/mi. This
is significant because it is in keeping with levels of heparin-like
molecules encountered in vivo [54]. In our cell culture studies,
heparin at these low concentrations must be added at the time of
serum stimulation of growth-arrested RMC for maximum inhibi-
tion of DNA synthesis. At high concentrations (100 jig/ml),
heparin can be added up to 18 hours after serum stimulation with
little or no loss of its antiproliferative effect on SMC [4]. Although
the mechanism of heparin's antiproliferative effect remains un-
known, multiple unidentified targets through the cell cycle have
been proposed [10]. The present study suggests that even at
E heparin concentrations below 1 jig/mi at least two mechanisms
contribute, one operating very early after stimulation (within 15
mm) before c-fos expression, and the other relatively insensitive to
the timing of events in early progression through G1.
— — + + — — Wright et al [55] examined the effects of heparin on the
expression of proto-oncogenes in murine fibroblasts and reported
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achieving the maximum antimitogenic activity of heparin and HS.
Unless the inhibition of c-fos expression is exquisitely sensitive
to intracellular heparin, the prolonged course of uptake of
1251-heparin from low extracellular concentrations suggests that at
least this component of heparin's effect at 15 minutes is not
dependent on internalization. Furthermore, there is a qualitative
association between heparin surface binding and its effect on the
mitogenic response. First, quiescent cultures of A10 cells had only
half the number of binding sites as RMC by Scatchard analysis
(3.6 x 106 vs. 6.6 X 106 sites/cell), and responded to the immediate
addition of heparin with a comparable decrease in the magnitude
of suppression of c-fos mRNA at 30 minutes (44% suppression
compared to control levels in A10 cells vs. 72% suppression in
RMC). Second, both the affinity and number of heparin binding
sites decreased in proliferating RMC cultures, representing a
significant portion of cycling cells that were found to be less
sensitive to suppression of [3H]-thymidine incorporation by hep-
arm. A similar decrease in specific heparin-binding sites of about
eightfold was found in exponentially growing vascular SMC as
compared to growth-arrested cells [17]. Conditions for the quan-
titative determination of binding parameters by equilibrium meth-
ods such as Scatchard analysis preclude measurements at discrete
points in the cell cycle. For instance, the equilibration time at low
heparin concentrations and the composition of the binding me-
dium required to minimize non-specific binding will themselves
influence progression through the cycle. We have, therefore,
compared quiescent cells with proliferating cells distributed
throughout the cycle to argue that the maximum number of
binding sites is present in G0. More detailed analysis awaits
molecular identification of the binding site itself. Nevertheless, if
endogenous heparin-like species are present in sufficient quanti-
ties to modulate cellular responses to mitogens, as our results with
HS1 and HS2 indicate [25 and this work], then regulation of the
number and affinity of heparin binding sites may be of physiolog-
ical significance.
Extracellular heparin may act by neutralizing mitogenic growth
factor activity, by interfering with growth factor-receptor binding,
by direct interaction with heparin-dependent signalling receptors,
or by altering the properties of the cell membrane. Although
heparin and HS assist in the delivery of active bFGF to its high
affinity receptor in fibroblasts [61, 62], they inhibit bFGF binding
and mitogenesis in vascular SMC [14]. Heparin also blocks
binding of thrombospondin—required for SMC proliferation—to
cell surfaces [16]. However, these mechanisms may not be as
important as heparin binding itself. Reilly, Fritze and Rosenberg
[44] reported that removal of heparin-binding proteins from
serum by chromatography on heparin-Sepharose does not alter
the antiproliferative properties of heparin. Likewise, in the
present study, passage of serum over heparin-Sepharose some-
what diminished its mitogenic potency but did not significantly
affect the magnitude of heparin's suppression of [3H]-thymidine
incorporation into DNA. More direct evidence for a role of
heparin independent of growth factors or growth factor receptors
is provided by the experiments with TPA. Under serum-free
conditions direct activation of PKC with phorbol ester leads to an
induction of c-fos that is still inhibited by heparin.
Internalization of HS chains during their metabolism can
involve release of intact chains at the cell surface [63] as well as in
intracellular compartments following endocytosis of HS proteo-
glycan [64]. Uptake of GPI-linked cell surface HS proteoglycan
following recognition of the phophoinositol moiety has also been
described [65]. While uptake and processing of heparin does
occur in the present study, the appearance of intracellular frag-
ments is too late to account for the full antimitogenic effect seen
with addition of heparin at the time of stimulation, or the lesser
effect observed when heparin is added 15 minutes later. Never-
theless, intracellular processing does appear to affect the subse-
quent antimitogenic potency of heparin-like species, and may
participate in determining the proliferative potential of cells when
they are allowed to accumulate in the culture medium or extra-
cellular space. Herbert and Maifrand [661 isolated heparin-de-
rived oligosaccharides from the media of endothelial cell cultures
after incubation with commercial heparin and found that they
were 10- to 15-fold more potent inhibitors of SMC proliferation
than heparin itself. Fragments of similar size produced by nitrous
acid depolymerization or heparin lyase digestion of standard
heparin were ineffective. We have reported that heparin lyase-
insensitive components of processed HS with little or no core
protein acumulate in the medium (H52) and cell layers (HS1) of
cultured RMC and have an increased antimitogenic potential
compared to heparin or HS proteoglycans [25]. As shown here,
they also suppress induction of c-fos mRNA when added together
with serum.
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